Homology Medicines, Inc.
Simbols: 0T6G.L
LSE
21.56
USDTirgus cena šodien
-0.7390
P/E koeficients
-0.0083
PEG koeficients
283.62M
MRK Cap
- 0.00%
DIV ienesīgums
Homology Medicines, Inc. (0T6G-L) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 82.7 | 175 | 155.9 | ||||||||
balance-sheet.row.short-term-investments | 0 | 43.4 | 141 | 47.5 | ||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.other-current-assets | 0 | 1.3 | 6 | 36 | ||||||||
balance-sheet.row.total-current-assets | 0 | 83.9 | 181 | 191.9 | ||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.7 | 21.6 | 17.9 | ||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 25.8 | 2 | ||||||||
balance-sheet.row.tax-assets | 0 | 221.6 | 0 | 0 | ||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-non-current-assets | 0 | 222.2 | 47.5 | 19.8 | ||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-assets | 0 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.account-payables | 0 | 3.2 | 1.1 | 2.4 | ||||||||
balance-sheet.row.short-term-debt | 0 | 1.3 | 1.6 | 0.2 | ||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.long-term-debt-total | 0 | 49.4 | 11.9 | 5 | ||||||||
Deferred Revenue Non Current | 0 | -104.4 | 0 | 1.2 | ||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||
balance-sheet.row.other-current-liab | 0 | 7 | 18.7 | 11.4 | ||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 221.6 | 27.9 | 24.8 | ||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.capital-lease-obligations | 0 | 6.8 | 27.9 | 23.7 | ||||||||
balance-sheet.row.total-liab | 0 | 233.1 | 50.5 | 42.1 | ||||||||
balance-sheet.row.preferred-stock | 0 | 111.4 | 111.4 | 111.4 | ||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.retained-earnings | 0 | -542.1 | -429.1 | -424.1 | ||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | -0.4 | 0 | ||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 503.6 | 496.1 | 482.3 | ||||||||
balance-sheet.row.total-stockholders-equity | 0 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 306.1 | 228.5 | 211.7 | ||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||
balance-sheet.row.total-equity | 0 | 73 | 178 | 169.7 | ||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||
Total Investments | 0 | 43.4 | 166.9 | 49.4 | ||||||||
balance-sheet.row.total-debt | 0 | 1.3 | 29.5 | 23.9 | ||||||||
balance-sheet.row.net-debt | 0 | -37.9 | -4.5 | -84.4 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -113 | -5 | -95.8 | ||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0.6 | 2.6 | 9.5 | ||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -19.2 | -38.8 | ||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 13.1 | 17.2 | ||||||||
cash-flows.row.change-in-working-capital | 0 | -7.2 | 3.4 | -41.8 | ||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.account-payables | 0 | 2.1 | -1 | -2.5 | ||||||||
cash-flows.row.other-working-capital | 0 | -9.3 | 4.3 | -39.3 | ||||||||
cash-flows.row.other-non-cash-items | 0 | 23.4 | -108.4 | 39.8 | ||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.acquisitions-net | 0 | 0.6 | 130 | 48.4 | ||||||||
cash-flows.row.purchases-of-investments | 0 | -73.2 | -157.5 | -97.4 | ||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 174.2 | 65.5 | 49 | ||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | -48.4 | ||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 101.3 | 36.7 | -50.8 | ||||||||
cash-flows.row.debt-repayment | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.common-stock-issued | 0 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 0.6 | 52.2 | ||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0.2 | 0.6 | 52.2 | ||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||
cash-flows.row.net-change-in-cash | 0 | 5.3 | -74.4 | -109 | ||||||||
cash-flows.row.cash-at-end-of-period | 0 | 39.3 | 34 | 108.4 | ||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 34 | 108.4 | 217.4 | ||||||||
cash-flows.row.operating-cash-flow | 0 | -96.2 | -113.7 | -109.8 | ||||||||
cash-flows.row.capital-expenditure | 0 | -0.2 | -1.3 | -2.4 | ||||||||
cash-flows.row.free-cash-flow | 0 | -96.5 | -114.9 | -112.1 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 1.2 | 3.2 | 34 | ||||||||
income-statement-row.row.cost-of-revenue | 0 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.gross-profit | 0 | 0.6 | 0.6 | 24.4 | ||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.operating-expenses | 0 | 92.7 | 133.9 | 120.4 | ||||||||
income-statement-row.row.cost-and-expenses | 0 | 93.3 | 136.5 | 129.9 | ||||||||
income-statement-row.row.interest-income | 0 | 5.6 | 3.2 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.total-operating-expenses | 0 | 5 | 134.5 | 0.2 | ||||||||
income-statement-row.row.interest-expense | 0 | 0 | 0 | 0 | ||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.6 | 2.6 | 9.5 | ||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||
income-statement-row.row.operating-income | 0 | -92.1 | -133.3 | -95.9 | ||||||||
income-statement-row.row.income-before-tax | 0 | -87.1 | 1.2 | -95.8 | ||||||||
income-statement-row.row.income-tax-expense | 0 | 0.3 | 0.7 | 0.5 | ||||||||
income-statement-row.row.net-income | 0 | -113 | -5 | -95.8 |
Biežāk uzdotie jautājumi
Kas ir Homology Medicines, Inc. (0T6G.L) kopējie aktīvi?
Homology Medicines, Inc. (0T6G.L) kopējie aktīvi ir 306119000.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir N/A.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 2.827.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -22.864.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir 8.364.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir 6.819.
Kāda ir Homology Medicines, Inc. (0T6G.L) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -112961000.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 1318000.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 92680000.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 0.000.